Slides and Webcasts from all ESMO Advanced Courses are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.
ESMO Advanced Course on Role of CDK4/6 Inhibitors in Hormone Receptor Positive HER2 Negative in Breast Cancer 2024: Jeddah
- Start date
- 07 Sep 2024
- End date
- 07 Sep 2024
- Location
- Jeddah, Saudi Arabia
Learning objectives
- Understanding the function and biology of CDK4-6 in breast cancer
- Information and in-depth discussion on the state of the art and emerging therapeutic strategies integrating CDK4-6 inhibition in breast cancer, both in the early and metastatic setting
- Assessing the clinical and genomic features for risk of relapse in early HR+/HER2 negative breast cancer
- Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of CDK4-6 inhibition
- Discussing clinical cancer cases to integrate use of CDK4-6 inhibitors in clinical practice
Co-Chairs
- Giuseppe Curigliano, Italy
- Barbara Pistilli, France
- Meteb Al-Foheidi, Saudi Arabia
Accreditation
The programme of this event has been accredited with 6 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Supported by
